Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Cash Flow Statement 
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Cytokinetics Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net loss (129,422) (128,637) (131,289) (137,380) (142,310) (19,820) (89,445) (30,570) (76,086) (61,554) (47,104) (43,930) (3,175) (40,780) (39,405) (30,640) (29,573) (32,113) (29,366) (26,468) (22,017) (27,523) (30,281)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements 6,886 6,349 6,313 9,241 8,994 7,031 6,592 4,297 2,985 2,900 2,822 5,673 5,481 5,932 5,706 5,533 5,321 5,064 4,819 4,741 4,559 4,338 4,129
Stock-based compensation expense 18,716 18,668 15,194 13,498 13,175 12,195 8,985 6,711 7,767 7,093 5,261 4,877 4,692 4,527 3,524 2,875 2,783 2,819 2,282 2,281 2,572 2,505 2,403
Non-cash lease expense 937 936 935 1,083 680 595 227 1,954 2,281 2,002 1,124 1,095 1,068 1,042 1,016 921 898 877 856
Impairment of right-of-use assets 2,844
Depreciation of property and equipment 1,854 1,855 1,848 1,658 1,408 1,407 1,341 734 462 543 537 471 536 416 408 391 336 280 286 (320) 268 618 673
(Gain) loss on investments, net 1 34 107 (573)
Interest receivable and amortization on investments (3,736) (3,861) (3,037) (4,218) (2,038) 542 1,004 1,454 1,424 1,083 933 (792) (429) (266) 293 (1,004) (375) (675) (533) (440) (737) (596) 96
Non-cash interest expense related to debt 7,079 6,983 6,888 1,088 1,967 1,342 1,300 1,875 1,825 1,749 1,676 1,691 1,648 1,577 1,724 112 291 333 183 508 (176) 411 177
Loss on extinguishment of debt 2,693
Loss on inducement of convertible debt 22,246
Accounts receivable (1,514) 21 (859) 2,147 (321) 4,083 50,763 (51,175) 2,057 1,813 (94) 545 (2,711) 450 2,459 1,413 2,417 (4,828) (1,934) 6,925 (8,920) (199) 1,075
Contract assets 575 1,897 2,082 (8,383) 4,499 5,826 3,212
Prepaid and other assets 342 (5,652) (1,627) 1,528 (909) (6,611) (1,422) 3,863 (5,663) (8,258) 2,677 (5,456) 454 (1,109) 949 (2,117) (1,479) 717 (983) (209) (162) 782 1,406
Accounts payable 1,235 (4,323) (8,106) 13,048 3,406 (8,850) (3,080) 3,857 (422) 1,667 (4,047) 1,312 3,818 (607) (4,633) 4,748 (1,782) 2,647 (1,217) 1,740 688 (1,087) (2,831)
Accrued and other liabilities 4,155 (11,426) (7,755) (351) 8,638 6,079 (3,522) 1,239 10,787 6,154 (3,120) 1,472 4,191 2,518 (1,064) (265) 1,320 (757) (2,466) 46 (512) (2,664) 1,067
Contract liabilities (8,132) (1,416) (9,202)
Operating lease liabilities (78) (74) (120) 671 1,114 522 (579) 10,006 11,996 11,654 9,816 (1,235) (1,206) (1,139) (1,112) (1,022) (1,000) (938) (916)
Other non-current liabilities (2,659) (2,645) (705) (203) (197) (1,990) (1,668) (1,826) 1,817 3,658
Deferred revenue (87,000) 87,000 7,252 (4,165) (7,841) (1,731)
Changes in operating assets and liabilities 1,481 (24,099) (19,172) 16,840 11,731 (93,767) 40,492 (34,036) 20,572 16,688 5,232 83,638 4,546 113 (3,401) 2,757 51 (1,262) (5,434) 7,371 (16,704) (6,599) (7,004)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities 33,217 6,832 9,003 39,190 58,270 (70,655) 62,634 (14,167) 37,316 32,058 17,585 96,080 17,542 13,341 9,270 11,585 9,305 7,436 2,459 14,141 (10,218) 677 474
Net cash provided by (used in) operating activities (96,205) (121,805) (122,286) (98,190) (84,040) (90,475) (26,811) (44,737) (38,770) (29,496) (29,519) 52,150 14,367 (27,439) (30,135) (19,055) (20,268) (24,677) (26,907) (12,327) (32,235) (26,846) (29,807)
Purchases of investments (117,725) (201,592) (89,779) (125,179) (467,177) (69,910) (193,127) (31,592) (321,589) (105,661) (66,200) (269,278) (138,681) (17,274) (10,592) (136,085) (41,637) (58,866) (41,295) (51,796) (56,220) (107,984) (24,224)
Maturities of investments 190,984 284,437 250,701 157,633 181,136 136,035 129,790 96,681 128,572 133,334 64,250 99,154 40,250 52,775 55,122 32,125 56,325 52,953 61,196 78,500 59,255 63,856 44,621
Sales of investments 4,977 3,300 3,061 3,196
Purchases of property and equipment (220) (717) (402) (3,205) (6,331) (857) (942) (17,754) (15,700) (8,792) (6,626) (6,555) (2,592) (864) (1,041) (1,306) (1,006) (50) (257) (210) (358) (60) (261)
Sales of property and equipment 14
Net cash (used in) provided by investing activities 73,039 82,128 165,497 29,249 (292,372) 65,268 (64,279) 47,335 (208,717) 18,881 (5,276) (173,618) (101,023) 34,637 43,489 (105,266) 13,682 (2,767) 19,644 26,508 2,677 (44,188) 20,136
Repayment of finance lease liabilities (217) (212) (207) (105) (424) (267) (148)
Repayment of term loan (47,651)
Debt extinguishment costs (2,409)
Repayment of convertible debt (140,330)
Proceeds from issuance of convertible debt, net 523,586 133,860
Proceeds from public offerings of common stock, net of discounts, commissions and offering cost 296,905 188,883
Proceeds from private placement, net 15,144 36,225
Proceeds from 2022 RPI Transactions, net 50,000 149,581
Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs 1,312 11,400 19,697 5,117
Proceeds from issuance of common stock under equity incentive and stock purchase plans 3,124 5,687 3,547 3,598 6,187 3,683 4,075 4,362 3,990 3,175 (3,596) 3,641 1,226 4,160 (2,162) 646 459 989 (701) 451 2,783 524 (524)
Taxes paid related to net share settlement of equity awards (10,517) (9,602)
Claims settlement under Section 16(b) 2,151
Cash settlement of capped call options associated with 2026 Notes 26,392
Net proceeds from long-term debt, net of debt discount and issuance costs 1,710 7,444 2,454
Purchase of capped call options associated with convertible notes (13,386)
Net cash provided by (used in) financing activities 54,219 5,475 (7,177) 29,885 389,019 3,416 93,846 19,506 300,895 3,175 (3,596) 3,641 226,334 4,160 (11) 121,120 11,859 22,396 4,416 451 10,227 2,978 (524)
Net increase (decrease) in cash, cash equivalents, and restricted cash 31,053 (34,202) 36,034 (39,056) 12,607 (21,791) 2,756 22,104 53,408 (7,440) (38,391) (117,827) 139,678 11,358 13,343 (3,201) 5,273 (5,048) (2,847) 14,632 (19,331) (68,056) (10,195)

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Cytokinetics Inc. net cash provided by (used in) operating activities increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Cytokinetics Inc. net cash (used in) provided by investing activities decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Cytokinetics Inc. net cash provided by (used in) financing activities increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.